Loading…
Loading…
Andra AP fonden increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 78.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,697 shares of the biopharmaceutical company's stock after acquiring an additional 38,157 shares during
Fifth Third Bancorp grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 7,433.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,568 shares of the biopharmaceutical company's stock after acquiring an additional 9,441 shares during the quarter. Fifth Third Bancorp's
Allspring Global Investments Holdings LLC grew its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 1.1% in the undefined quarter, according to its most recent filing with the SEC. The firm owned 281,793 shares of the biopharmaceutical company's stock after buying an additional 3,136 shares during the quarter. Allspring Global Investments Holdings LLC
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2026 on Thursday, July 30, 2026, before the U.S. financial markets open. Management will provide an update on the Company and discuss second quarter 2026 results as well as expectations for the future via conference call on Thursday, July 30, 2026 at 8:30 am ET. A live audio webcast of.
I initiate coverage of Alnylam Pharmaceuticals with a non-consensus BUY rating, citing the recent pullback as an overreaction. AMVUTTRA now holds a near-term commercial monopoly in TTR silencing, with strong clinical data and $890 million in Q1 2026 revenue. ALNY's robust cash position ($3.0 billion) and GAAP profitability materially reduce investment risk and support pipeline development.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today shared advances across its growing neuroscience portfolio at the Alzheimer's Association International Conference (AAIC) 2026. This scientific progress underscores the potential of RNAi therapeutics to address the needs of patients with debilitating neurological diseases. Mivelsiran: An investigational RNAi therapeutic targeting amyloid precursor protein (APP) in develop.
When a late-stage clinical trial misses a primary endpoint, the market reaction rarely distributes evenly across the board. The fallout often reveals undeniable fundamental truths about single-asset exposure, pipeline diversification, and the competitive moats protecting established treatments.
CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for ALNY and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.